"Expanding our operational capabilities"

Prolysis' in-house scientific team is complemented by strategic partnerships with industrial organisations and leading research institutions.

By building these partnerships, Prolysis benefits through access to expertise, technology and infrastructure without incurring major capital investment. Our approach reflects the value that can be created through flexible, synergistic and mutually-beneficial collaborations.

To date, Prolysis has developed key partnerships covering drug discovery, synthetic chemistry, cell and molecular biology, biochemistry and structural biology and cheminformatics. 

We will add further operational capabilities as required to progress our products to the clinic.